02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 .
Japan s ONO pays $2 4 billion for Qinlock-maker Deciphera fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk. Earnings & Valuation This table compares Puma […]
Critical Review: Shattuck Labs (NASDAQ:STTK) versus Ovid Therapeutics (NASDAQ:OVID) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired.